|
|
 Previous Article | Table of Contents | Next Article 
Blood, Vol. 93 No. 5 (March 1), 1999:
pp. 1697-1706
Ibandronate Reduces Osteolytic Lesions but not Tumor Burden in a
Murine Model of Myeloma Bone Disease
Sarah L. Dallas,
I. Ross Garrett,
Babatunde O. Oyajobi,
Mark R. Dallas,
Brendan F. Boyce,
Frieder Bauss,
Jiri Radl, and
Gregory R. Mundy
From the Department of Medicine (Division of Endocrinology and
Metabolism), and the Department of Pathology, University of Texas
Health Science Center at San Antonio, TX; the Department of Preclinical
Research and Development, Bone Metabolism, Boehringer Mannheim,
Germany; and TNO Institute for Prevention and Health, Leiden, the
Netherlands.
We determined the effects of the potent bisphosphonate ibandronate
in a murine model of human myeloma bone disease. In this model, bone
lesions typical of the human disease develop in mice following
inoculation of myeloma cells via the tail vein. Treatment with
ibandronate (4 µg per mouse per day) significantly reduced the
occurrence of osteolytic bone lesions in myeloma-bearing mice. However,
ibandronate did not prevent the mice from developing hindlimb paralysis
and did not produce a detectable effect on survival. There was no
significant effect of ibandronate on total myeloma cell burden, as
assessed by morphometric measurements of myeloma cells in the bone
marrow, liver, and spleen, or by measurement of serum IgG2b levels.
These results support clinical findings that bisphosphonates may be
useful for the treatment of myeloma-associated bone destruction, but
suggest that other therapies are also required to reduce tumor growth.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
E. Terpos, O. Sezer, P. I. Croucher, R. Garcia-Sanz, M. Boccadoro, J. San Miguel, J. Ashcroft, J. Blade, M. Cavo, M. Delforge, et al.
The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network
Ann. Onc.,
May 22, 2009;
(2009)
mdn796v1.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. Murillo, A. Arina, S. Hervas-Stubbs, A. Gupta, B. McCluskey, J. Dubrot, A. Palazon, A. Azpilikueta, M. C. Ochoa, C. Alfaro, et al.
Therapeutic Antitumor Efficacy of Anti-CD137 Agonistic Monoclonal Antibody in Mouse Models of Myeloma
Clin. Cancer Res.,
November 1, 2008;
14(21):
6895 - 6906.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Hong, J. Qian, J. Yang, H. Li, L. W. Kwak, and Q. Yi
Roles of Idiotype-Specific T Cells in Myeloma Cell Growth and Survival: Th1 and CTL Cells Are Tumoricidal while Th2 Cells Promote Tumor Growth
Cancer Res.,
October 15, 2008;
68(20):
8456 - 8464.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. M. Edwards, J. R. Edwards, S. T. Lwin, J. Esparza, B. O. Oyajobi, B. McCluskey, S. Munoz, B. Grubbs, and G. R. Mundy
Increasing Wnt signaling in the bone marrow microenvironment inhibits the development of myeloma bone disease and reduces tumor burden in bone in vivo
Blood,
March 1, 2008;
111(5):
2833 - 2842.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Goel, S. K. Carlson, K. L. Classic, S. Greiner, S. Naik, A. T. Power, J. C. Bell, and S. J. Russell
Radioiodide imaging and radiovirotherapy of multiple myeloma using VSV({Delta}51)-NIS, an attenuated vesicular stomatitis virus encoding the sodium iodide symporter gene
Blood,
October 1, 2007;
110(7):
2342 - 2350.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. O. Oyajobi, S. Munoz, R. Kakonen, P. J. Williams, A. Gupta, C. L. Wideman, B. Story, B. Grubbs, A. Armstrong, W. C. Dougall, et al.
Detection of myeloma in skeleton of mice by whole-body optical fluorescence imaging
Mol. Cancer Ther.,
June 1, 2007;
6(6):
1701 - 1708.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Goel, A. Dispenzieri, S. M. Geyer, S. Greiner, K.-W. Peng, and S. J. Russell
Synergistic activity of the proteasome inhibitor PS-341 with non-myeloablative 153-Sm-EDTMP skeletally targeted radiotherapy in an orthotopic model of multiple myeloma
Blood,
May 15, 2006;
107(10):
4063 - 4070.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. O. Oyajobi, C. M. Shipman, and G. R. Mundy
Recent Insights into Myeloma Bone Disease
IBMS BoneKEy,
May 1, 2005;
2(5):
17 - 25.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. L. Olson, L. C. Burkly, D. R. Leone, B. M. Dolinski, and R. R. Lobb
Anti-{alpha}4 integrin monoclonal antibody inhibits multiple myeloma growth in a murine model
Mol. Cancer Ther.,
January 1, 2005;
4(1):
91 - 99.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Mori, N. Shimizu, M. Dallas, M. Niewolna, B. Story, P. J. Williams, G. R. Mundy, and T. Yoneda
Anti-{alpha}4 integrin antibody suppresses the development of multiple myeloma and associated osteoclastic osteolysis
Blood,
October 1, 2004;
104(7):
2149 - 2154.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. O. Oyajobi, G. Franchin, P. J. Williams, D. Pulkrabek, A. Gupta, S. Munoz, B. Grubbs, M. Zhao, D. Chen, B. Sherry, et al.
Dual effects of macrophage inflammatory protein-1{alpha} on osteolysis and tumor burden in the murine 5TGM1 model of myeloma bone disease
Blood,
July 1, 2003;
102(1):
311 - 319.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. C. Anderson, J. D. Shaughnessy Jr., B. Barlogie, J.-L. Harousseau, and G. D. Roodman
Multiple Myeloma
Hematology,
January 1, 2002;
2002(1):
214 - 240.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
B. O. Oyajobi, D. M. Anderson, K. Traianedes, P. J. Williams, T. Yoneda, and G. R. Mundy
Therapeutic Efficacy of a Soluble Receptor Activator of Nuclear Factor {{kappa}}B-IgG Fc Fusion Protein in Suppressing Bone Resorption and Hypercalcemia in a Model of Humoral Hypercalcemia of Malignancy
Cancer Res.,
March 1, 2001;
61(6):
2572 - 2578.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
N. Raje and K. C. Anderson
Introduction: the evolving role of bisphosphonate therapy in multiple myeloma
Blood,
July 15, 2000;
96(2):
381 - 383.
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Asosingh, U. Gunthert, M. H. C. Bakkus, H. De Raeve, E. Goes, I. Van Riet, B. Van Camp, and K. Vanderkerken
In Vivo Induction of Insulin-like Growth Factor-I Receptor and CD44v6 Confers Homing and Adhesion to Murine Multiple Myeloma Cells
Cancer Res.,
June 1, 2000;
60(11):
3096 - 3104.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. C. Anderson, R. A. Kyle, W. S. Dalton, T. Landowski, K. Shain, R. Jove, L. Hazlehurst, and J. Berenson
Multiple Myeloma: New Insights and Therapeutic Approaches
Hematology,
January 1, 2000;
2000(1):
147 - 165.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
